Literature DB >> 22892341

Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.

Andrew J Kwilasz1, S Stevens Negus.   

Abstract

Cannabinoid receptor agonists produce reliable antinociception in most preclinical pain assays but have inconsistent analgesic efficacy in humans. This disparity suggests that conventional preclinical assays of nociception are not sufficient for the prediction of cannabinoid effects related to clinical analgesia. To extend the range of preclinical cannabinoid assessment, this study compared the effects of the marijuana constituent and low-efficacy cannabinoid agonist Δ9-tetrahydrocannabinol (THC) and the high-efficacy synthetic cannabinoid agonist 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol (CP55940) in assays of pain-stimulated and pain-depressed behavior. Intraperitoneal injection of dilute lactic acid (1.8% in 1 ml/kg) stimulated a stretching response or depressed intracranial self-stimulation (ICSS) in separate groups of male Sprague-Dawley rats. THC (0.1-10 mg/kg) and CP55940 (0.0032-0.32 mg/kg) dose-dependently blocked acid- stimulated stretching but only exacerbated acid-induced depression of ICSS at doses that also decreased control ICSS in the absence of a noxious stimulus. Repeated THC produced tolerance to sedative rate-decreasing effects of THC on control ICSS in the absence of the noxious stimulus but failed to unmask antinociception in the presence of the noxious stimulus. THC and CP55940 also failed to block pain-related depression of feeding in rats, although THC did attenuate satiation-related depression of feeding. In contrast to the effects of the cannabinoid agonists, the clinically effective analgesic and nonsteroidal anti-inflammatory drug ketoprofen (1 mg/kg) blocked acid-stimulated stretching and acid-induced depression of both ICSS and feeding. The poor efficacy of THC and CP55940 to block acute pain-related depression of behavior in rats agrees with the poor efficacy of cannabinoids to treat acute pain in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892341      PMCID: PMC3477211          DOI: 10.1124/jpet.112.197780

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

Review 1.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.

Authors:  Robert H Dworkin; Dennis C Turk; John T Farrar; Jennifer A Haythornthwaite; Mark P Jensen; Nathaniel P Katz; Robert D Kerns; Gerold Stucki; Robert R Allen; Nicholas Bellamy; Daniel B Carr; Julie Chandler; Penney Cowan; Raymond Dionne; Bradley S Galer; Sharon Hertz; Alejandro R Jadad; Lynn D Kramer; Donald C Manning; Susan Martin; Cynthia G McCormick; Michael P McDermott; Patrick McGrath; Steve Quessy; Bob A Rappaport; Wendye Robbins; James P Robinson; Margaret Rothman; Mike A Royal; Lee Simon; Joseph W Stauffer; Wendy Stein; Jane Tollett; Joachim Wernicke; James Witter
Journal:  Pain       Date:  2005-01       Impact factor: 6.961

2.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

3.  CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

Authors:  Styliani Vlachou; George G Nomikos; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

4.  Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.

Authors:  J De Vry; K R Jentzsch; E Kuhl; G Eckel
Journal:  Behav Pharmacol       Date:  2004-02       Impact factor: 2.293

5.  Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response.

Authors:  D Raft; J Gregg; J Ghia; L Harris
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

Review 6.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

7.  Spinal and supraspinal components of cannabinoid-induced antinociception.

Authors:  A H Lichtman; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1991-08       Impact factor: 4.030

8.  Hyperphagia in pre-fed rats following oral delta9-THC.

Authors:  C M Williams; P J Rogers; T C Kirkham
Journal:  Physiol Behav       Date:  1998-11-15

9.  Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol.

Authors:  E L Gardner; W Paredes; D Smith; A Donner; C Milling; D Cohen; D Morrison
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Pain-like behaviours in animals - how human are they?

Authors:  Gordon Blackburn-Munro
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

View more
  41 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

Review 2.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

3.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

4.  Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.

Authors:  Megan J Moerke; S Stevens Negus
Journal:  Neuropharmacology       Date:  2019-03-14       Impact factor: 5.250

5.  Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Authors:  J A Suyama; M L Banks; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

6.  Tolerance to hypothermic and antinoceptive effects of ∆9-tetrahydrocannabinol (THC) vapor inhalation in rats.

Authors:  Jacques D Nguyen; Yanabel Grant; Tony M Kerr; Arnold Gutierrez; Maury Cole; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2018-07-19       Impact factor: 3.533

7.  Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.

Authors:  Andrew J Kwilasz; Rehab A Abdullah; Justin L Poklis; Aron H Lichtman; Sidney S Negus
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

8.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

Review 9.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

10.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.